Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

LSP

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 3
Average round size
info
The average size of a deal this fund participated in
$33M
Portfolio companies 3
Lead investments 2
Key employees Soon

Areas of investment

  • Medical Device
  • Health Care
  • Therapeutics
  • Manufacturing
  • Biotechnology
Summary

Moreover, a startup needs to be at the age of 11-15 years to get the investment from the fund. Among the most successful fund investment fields, there are Medical Device, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight iSTAR Medical, Xeltis. The fund has specific favorite in a number of founders of portfolio startups.

The standard case for the fund is to invest in rounds with 4 partakers. Despite the LSP, startups are often financed by VI Partners AG, Life Sciences Partners, Kurma Partners. The meaningful sponsors for the fund in investment in the same round are SFPI-FPIM, S.R.I.W., Gimv.

The top activity for fund was in 2019. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 deals per year.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of LSP:
Typical Co-investors
LSP is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after LSP:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
301 Ventures College Park, Maryland, United States
AWI Ventures Australia, New South Wales, Sydney
AZURE PLUS Chiyoda, Japan
Chengdu High-tech Zone Venture Angel Fund Chengdu, China, Sichuan
CICC Healthcare Investment Fund Beijing, Beijing, China
Family and Friends Investment -
Flywheel Ventures New Mexico, Santa Fe, United States
Grey New York, New York, United States
Henley Ventures British Columbia, Canada, Surrey
Highlander Venture Fund -
Huilun Biological Technology China, Shanghai
Massachusetts Office of International Trade and Investment (MOITI) -
Mayham Holding AG -
Mike Egan -
Providence St. Joseph Health Renton, United States, Washington
Sapphire Capital Partners England, London, United Kingdom
Spire Capital New York, New York, United States
Tempus Partners Australia, New South Wales, Sydney
Zhejiang Changxing Economic and Technological Development China, Huzhou, Zhejiang
ZTE China, Guangdong, Shenzhen

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

eTheRNA immunotherapies

Biotechnology
Medical Device
Therapeutics
$40M16 Jun 2020 Belgium, Brussels-Capital

Xeltis

Health Care
Medical Device
Therapeutics
$12M06 Sep 2019 Zurich, Switzerland

iSTAR Medical

Health Care
Manufacturing
Medical Device
$47M05 Sep 2019 Belgium, Antwerp, Belgium
News
Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent LSP?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: